Clinical Trial Update: Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a monoclonal antibody therapy in combination with docetaxel for metastatic or recurrent breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Monoclonal antibody therapy

Snippet

Sponsor: Seagen Inc. | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED